Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease.
Andrea Zawacki BeatonEmmy OkelloJoselyn RwebemberaAnneke GroblerDaniel EngelmanJuliet AlepereLesley CanalesJonathan CarapetisAlyssa DeWyerPeter LwabiMariana MirabelAna O MocumbiMeghna MuraliMiriam NakittoEmma NdagireMaria C P NunesIsaac O OmaraRachel SarnackiAmy ScheelNigel WilsonMeghan ZimmermanLiesl ZühlkeGanesan KarthikeyanCraig A SableAndrew C SteerPublished in: The New England journal of medicine (2021)
Among children and adolescents 5 to 17 years of age with latent rheumatic heart disease, secondary antibiotic prophylaxis reduced the risk of disease progression at 2 years. Further research is needed before the implementation of population-level screening can be recommended. (Funded by the Thrasher Research Fund and others; GOAL ClinicalTrials.gov number, NCT03346525.).